Advertisement
Canada markets closed
  • S&P/TSX

    24,471.17
    +168.87 (+0.69%)
     
  • S&P 500

    5,857.52
    +42.49 (+0.73%)
     
  • DOW

    43,035.26
    +171.40 (+0.40%)
     
  • CAD/USD

    0.7249
    -0.0020 (-0.28%)
     
  • CRUDE OIL

    74.13
    -1.43 (-1.89%)
     
  • Bitcoin CAD

    90,731.83
    +4,584.09 (+5.32%)
     
  • XRP CAD

    0.75
    +0.03 (+3.62%)
     
  • GOLD FUTURES

    2,665.30
    -11.00 (-0.41%)
     
  • RUSSELL 2000

    2,244.31
    +9.90 (+0.44%)
     
  • 10-Yr Bond

    4.0980
    +0.0250 (+0.61%)
     
  • NASDAQ

    18,502.31
    +159.37 (+0.87%)
     
  • VOLATILITY

    19.81
    -0.65 (-3.18%)
     
  • FTSE

    8,292.66
    +39.01 (+0.47%)
     
  • NIKKEI 225

    39,605.80
    +224.90 (+0.57%)
     
  • CAD/EUR

    0.6645
    +0.0003 (+0.05%)
     

Longeveron Full Year 2023 Earnings: EPS Misses Expectations

Longeveron (NASDAQ:LGVN) Full Year 2023 Results

Key Financial Results

  • Net loss: US$22.2m (loss widened by 18% from FY 2022).

  • US$1.02 loss per share (further deteriorated from US$0.90 loss in FY 2022).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Longeveron EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.4%.

Looking ahead, revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 4.2% from a week ago.

Risk Analysis

Before you take the next step you should know about the 6 warning signs for Longeveron (2 are a bit unpleasant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.